Back HCV Treatment

FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment

On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.


Read more: